Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Oric Pharmaceuticals, Inc. - Common Stock (NQ:ORIC)

7.475 -5.195 (-41.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	15,611,249
Open	10.25
Bid (Size)	7.510 (2,500)
Ask (Size)	7.530 (1,300)
Prev. Close	12.67
Today's Range	7.370 - 10.80
52wk Range	3.895 - 14.93
Shares Outstanding	54,532,614
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Top movers analysis one hour before the close of the markets on 2026-04-01: top gainers and losers in today's session. ↗

Today 15:00 EDT

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

Today 12:30 EDT

Via Chartmill

Performance

YTD	-8.5%	-8.5%
1 Month	-46.1%	-46.1%
3 Month	-7.5%	-7.5%
6 Month	-37.7%	-37.7%
1 Year	+34.0%	+34.0%

More News

What's Behind The Drop In Oric Pharmaceuticals Stock Today? ↗

Today 11:08 EDT

Via Benzinga

These stocks are gapping in today's session ↗

Today 10:30 EDT

Via Chartmill

Which stocks are moving before the opening bell on Wednesday? ↗

Today 8:30 EDT

Via Chartmill

Top movers in Tuesday's after hours session ↗

March 31, 2026

Via Chartmill

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

March 31, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

March 27, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Via The Motley Fool

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

March 17, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

Via Benzinga

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

February 23, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

February 05, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

January 12, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

December 04, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

December 03, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

December 01, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

From ORIC Pharmaceuticals

Via GlobeNewswire

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Oric Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Oric Pharmaceuticals, Inc. - Common Stock trade on?

Oric Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Oric Pharmaceuticals, Inc. - Common Stock is ORIC on the Nasdaq Stock Market

What is the current price of Oric Pharmaceuticals, Inc. - Common Stock?

The current price of Oric Pharmaceuticals, Inc. - Common Stock is 7.475

When was Oric Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Oric Pharmaceuticals, Inc. - Common Stock was at 04/01/26 04:00 PM ET

What is the market capitalization of Oric Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Oric Pharmaceuticals, Inc. - Common Stock is 407.63M

How many shares of Oric Pharmaceuticals, Inc. - Common Stock are outstanding?

Oric Pharmaceuticals, Inc. - Common Stock has 408M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.